Neuroendocrine tumors in the Iran Cancer Institute: Predictive Factors of Patient Survival

  • Sadighi, Sanambar (Department of Internal Medicine, Cancer Research Center, Tehran University of Medical Sciences) ;
  • Roshanaee, Ghodratollah (Biostatistics Department, Hamadan University of Medical Sciences) ;
  • Vahedi, Saba (Department of Internal Medicine, Cancer Research Center, Tehran University of Medical Sciences) ;
  • Jahanzad, Easa (Department of Pathology, Cancer Research Center, Tehran University of Medical Sciences) ;
  • Mohagheghi, Mohammad Ali (Department of Surgical Oncology, Cancer Research Center, Tehran University of Medical Sciences) ;
  • Mousavi-Jarahi, Alireza (Department of Social Medicine, Shahid Beheshti University of Medical Sciences)
  • Published : 2014.10.11


Background: Neuroendocrine tumors have widespread and different clinical presentations and prognoses. This study was conducted to assess their survival time and prognostic factors in Iran. Materials and Methods: In a retrospective cohort study, 189 patients diagnosed of having neuroendocrine carcinoma were chosen. The tumor and clinical characteristics of the patients were modeled with a Cox proportional hazard approach. Survival was assessed using Kaplan-Meyer curves. Results: Crude median survival time was 30 months. Women survived longer than men (the median survival time for women was 40 and for men was 24 months). Age (<60 vs >60 years old with hazard ratio (HR) of 2.43, 95% CI 1.3-4.5), primary pathology report (carcinoid vs. others with HR 5.85 cm, 95% CI 2.4-14.3), tumor size cm (for 5-10, HR of 3.1, 95% CI 1.6 and for >10 HR of 8.2, 95% with 95% CI 3.1-21.9), and chemotherapy with single drug (taking vs. not taking with a HR 2.2, 95% CI 1.1-4.8) had significant effects on overall survival of patients. Conclusions: Survival time in patients with neuroendocrine carcinomas is related to demographics, clinical characteristics, tumor histology, and subtype specific treatment.


  1. Al-khafaji B, Noffsinger A, Miller M, et al (1999). Immunohistologic analysis of GI and pulmonary carcinoid tumors. Hum Pathol, 29, 992.
  2. Bernick P, Klimstra S, Shia Jea (2004). Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum, 47, 163-9.
  3. Brenner B, Shah M, Gonen M (2004). Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer, 90, 1720-6.
  4. Demirci U, Coskun U, Karaca H, et al (2014). Docetaxel and cisplatin in first line treatment of patients with unknown primary cancer: a multicenter study of the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 15, 1581-4.
  5. Durante C, Boukheris H, Dromain C, et al (2009). Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer, 16, 585-97.
  6. Fujii H, Aotake T, Horiuchi T et al (2001). Small cell carcinoma of the gallbladder: a case 45 report and review of 53 cases in the literature. Hepatogastroenterology, 48, 1588-93.
  7. Galanis E, Frytak S, Lloyd R (1997). Extrapulmonary small cell carcinoma. Cancer, 79, 1729-36.<1729::AID-CNCR14>3.0.CO;2-#
  8. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G (2010). Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the national cancer registry of Spain (RGETNE). Ann Oncol, 21, 1794-803.
  9. Harkema J, Jones S, Naydan D, Wilson D (1992). An atypical neuroendocrine carcinoma in the lung of a beagle dog. Vet Pathol, 29, 175-9.
  10. Junker K, Wiethege T, Muller K (2000). Pathology of small-cell lung cancer. J cancer Res clin oncol, 7, 361-8.
  11. Kang H, O'Connell J, Leonardi M (2007). Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis, 22, 183-9.
  12. Kulve M, Mayer R (1999). Carcinoid tumors. N Engl J Med, 340, 858-68.
  13. Lee S, Lee J, Ryu M (2007). Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol, 46, 846-51.
  14. Medrano-Guzman R, Lopez-Garcia SC, Torres-Vargas S, Gonzalez-Rodriguez D, Alvarado-Cabrero I (2011). Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival. Cirugia y Cirujanos, 79, 459-564.
  15. Modlin I, Lye K, Kidd M (2003). A 5-decade analysis of 13, 715 carcinoid tumors. Cancer, 97, 934-59.
  16. Modlin I, Oberg K, Chung D, et al (2008). Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol, 9, 61-72.
  17. Moertel C, Kvols L, O'Connell M (1991). Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 68, 227-32.<227::AID-CNCR2820680202>3.0.CO;2-I
  18. Sadighi S, Jahanzad I, Ghadirian L, et al (2013). Assessing the prevalence and characteristics of neuroendocrine tumors in patients attending Tehran Imam Khomeiny referral hospital. J Mazand Univ Med Sci, 23, 232-6.
  19. Sorbye H, Welin S, Langer SW, et al (2013). Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol, 24, 152-60.
  20. Wang Y-h, Lin Y, Xue L, et al (2012). Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China. BMC Endocr Disord, 12, 30-9.
  21. Wu B, Hu Y, Sun J, et al (2014). Analysis on the characteristics and prognosis of pulmonary neuroendocrine tumors. Asian Pac J Cancer Prev, 15, 2205-10.
  22. Yao J, Hassan M, Phan A, et al (2008). One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 26, 3063-72.
  23. Yocel B, Babakan NAKanan T, Ayeren A (2013). Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pac J Cancer Prev, 14, 6687-92.
  24. Zeng YJ, Liv L, We H, et al (2013). Clinicopathologic features and prognosis of GIP neuroendocrine tumors:Analysis from a single institution. Asian Pac J Cancer Prev, 14, 5775-81.